References
- Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Surg 2007;23:65–66
- Saif MW, Gnanaraj J. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutan Ocul Toxicol 2010;29:62–66
- Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthal Plast Surg 2007;23:63–65
- Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 2013;21:1167–1174
- Johnson KS, Levin F, Chu DS. Persistent corneal epithelial defect associated with erlotinib treatment. Cornea 2009;28:706–707
- Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology 2012;119:1798–1802
- Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res 2001;72:511–517
- Ambrosio R Jr, Wilson SE. Complications of laser in situ keratomileusis: etiology, prevention, and treatment. J Refract Surg 2001;17:350–379
- William N, Charman DSc. Mismatch between flap and stromal areas after laser in situ keratomileusis as source of flap striae. J Cataract Refract Surg 2002;28:2146–2152